# US 2013/0252886 A1 · Methods of delaying and treating diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252886 A1
- Document ID: US20130252886A1
- Status: Published application
- Kind: A1
- Application number: 13/880,907
- Filed: 2011-10-21
- Published: 2013-09-26
- Earliest claimed: 2010-10-22
- Inventors: Brooke Ligon
- Web page: https://patentgrep.com/patent/US20130252886A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods of treating hyperglycemia and delaying the onset of diabetes, comprising administering to a mammal in need thereof a therapeutically effective amount of a GABA receptor agonist at or near a time of an exogenous insulin administration or a meal.

## Claims

### Claim 1

A method of delaying the onset of diabetes in a mammal subject to developing diabetes comprising:
periodically administering to said mammal an effective diabetes-delaying amount of a GABA receptor agonist at or near ingestion of meals by said mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the GABA receptor agonist comprises GABA.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammal is a human or a canine.

### Claim 4 (depends on 3)

The method of claim 3, wherein the effective diabetes delaying amount of the GABA receptor agonist is an amount from about 30 mg/kg to about 120 mg/kg.

### Claim 5

A method of reducing the insulin dosage in a mammal being treated for diabetes with periodic exogenous administration of insulin comprising:
co-administering an effective insulin-reducing amount of a GABA receptor agonist at or near the periodic administration of insulin.

### Claim 6 (depends on 5)

The method of claim 5, wherein the GABA receptor agonist comprises GABA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the mammal is a human.

### Claim 8 (depends on 7)

The method of claim 7, wherein the effective insulin-reducing amount of the GABA receptor agonist comprises at least 30 mg/kg (60).

### Claim at position 9

9-16. (canceled)

### Claim 17

A kit comprising:
a GABA receptor agonist and insulin.

### Claim 18 (depends on 17)

The kit of claim 17 wherein the GABA receptor agonist comprises GABA.
